№ |
73(2):328–35. |
(https://elibrary.ru/contents.asp? |
issueid=1838606&selid=29381428) |
|
|
37.Якунина И.А., Ильиных Е.В., Удельнова И.А. и др. Частота выявления симптома «пробойника при рентгенологическом исследовании дистальных отделов стоп больных с подагрой: связь с длительностью болезни и течением артрита. Науч.-практ.
ревматология. 2003; (2):222-231. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
38.Khoo J.N., Tan S.C. MR imaging of tophaceous gout revisited.
Singapore Med. J. 2011;52 (11):840–847. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
39.Dhôte R., Roux F.X., Bachmeyer C., Tudoret L., Daumas-Duport C., Christoforov B. Extradural spinal tophaceous gout: evolution with medical treatment. Clin. Exp. Rheumatol. 1997;15(4):421-3. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
40.McCarthy G.M., Barthelemy C.R., Veum J.A., Wortmann R.L. Influence of antihyperuricemic therapy on the clinical and radiographic progression ofgout. Arthritis Rheum. 1991;(34):1489– 1494. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
41.Rundles R.W., Metz E.N., Silberman H.R. Allopurinol in the treatment of gout. Ann Intern Med 1966; (64):229–58. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
42.Zhang W., Doherty M., Bardin T., et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 2006;65(10):1312–24. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
43.Rosenfeld J.B. Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects. Adv. Exp. Med. Biol. 1974; (41):581–96. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
44.Perez-Ruiz F., Calabozo M., Jose Fernandez-Lopez M., Herrero-Beites A., Ruiz-Lucea E., Garcia-Erauskin G., et al. Treatment of chronic gout in patients with renal function impairment: An open, randomized, actively controlled study. J. Clin. Rheumatol. 1999; (5):49-55. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
45.Khanna D., Fitzgerald J.D., Khanna P.P., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken). 2012;64
(10):1431–1446. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
46.Altman R.D., Honig S., Levin J.M., Lightfoot R.W. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, doubleblind comparative study. J. Rheumatol. 1988;(15):1422–1426. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
47.Klumb E.M., Pinheiro G.R.C., Ferrari A., Albuquerque E.M.N. The treatment of acute gout arthritis. Double-blind randomized comparative study between nimesulid and indomethacin. Rev. Brasil. Med. 1996; (53):540–6. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
48.Lederman R. A double-blind comparison of Etodolac (Lodine (R)) and high doses of naproxen in the treatment of acute gout. Adv. Ther. 1990;(7):344–54. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
49.Reardon J.A., Stockman A., Darlington L.G., Scott J.T. Double-blind trial of feprazone and phenylbutazone in acute gout. Curr. Med. Res. Opin. 1980; (6):445–8. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
50.Ruotsi A., Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial.
Scand. J. Rheumatol. Suppl 1978;(21):15–17. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
51.Shrestha M., Morgan D.L., Moreden J.M., Singh R., Nelson M., Hayes J.E. Randomized double blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann. Emerg. Med. 1995;(26):682–6. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
52.Siegmeth W., Placheta P. Double-blind trial: ketoprofen versus phenylbutazone in acute gouty arthritis (author’s translation) [in German]. Wiener Klinische Wochenschrift. 1976; (88):535–7. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
53.Weiner G.I., White S.R., Weitzner R.I., Rubinstein HM. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979; (22):425–6. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
54.Terkeltaub R.A., Furst D.E., Bennett K., et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-
controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060-1068. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
55.Groff G.D., Franck W.A., Raddatz D.A. Systemic steroid therapy for acute gout: a clinical trial and review of the literature [review] [40 refs]. Semin. Arthritis. Rheum. 1990;(19):329–36. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
56.Janssens H.J. et al. Use of oral prednisolone or naproxen for the
treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008; 371 (9627):1854-60. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
57.Федорова А.А., Барскова В.Г., Якунина И.А., Насонова В.А., Насонов Е.Л. Кратковременное применение глюкокортикоидов у больных с затяжным и хроническим подагрическим артритом. Часть IIсравнение эффективности различных лекарственных форм. Научно-практ. ревматология.2008;(5):72-75. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
58.So A., De Meulemeester M., Pikhlak A., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010; 62(10):3064-76. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
59.Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine 2015;(82):141–3. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
60.Pascual E., Sivera F. Time required for disappearance of urate crystals
from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann. Rheum. Dis. 2007;(66):1056–8. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
61.Perez-Ruiz F., Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007; (57):1324–8. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
62.Perez-Ruiz F., Calabozo M., Pijoan J.I.,et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Arthritis Rheum. 2002; (47):356–60. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
63.Schretlen D.J., Inscore A.B., Vannorsdall T.D., et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; (69):1418–23. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
64.Chen H., Mosley T.H., Alonso A., et al. Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am. J. Epidemiol. 2009; (169):1064–9. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
65. Weisskopf M.G., O’Reilly E., Chen H., et al. Plasma urate and risk of Parkinson’s disease. Am. J. Epidemiol. 2007; (166):561–7. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
66.Kim T.S., Pae C.U., Yoon S.J., et al. Decreased plasma antioxidants in patients with Alzheimer’s disease. Int. J. Geriatr. Psychiatry. 2006; (21):344–8. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
67.Abraham A., Drory V.E. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-
analysis. J. Neurol. 2014; (261):1133–8. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
68.Stamp L.K., Taylor W.J., Jones P.B., et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012; (64):2529–36. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
69.Stamp L.K., O"Donnell J.L., Zhang M., et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011; № 63 (2):412-21. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
70.Chao J., Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr. Rheumatol. Rep.
2009; |
(11):135–40. |
(https://elibrary.ru/contents.asp? |
issueid=1838606&selid=29381428) |
|
|
71.Stamp L.K., Chapman P.T., Barclay M.L., Horne A., Frampton C., Tan P, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann. Rheum. Dis. 2017; 76 (9):1522–8. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
72.Schumacher H.R. Jr., Becker M.A., Wortmann R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double blind, parallel-group trial. Arthritis Rheum. 2008; 59(11):1540–1548. (https://elibrary.ru/contents.asp? issueid=1838606&selid=29381428)
73.Iwona Słowińska, Radosław Słowiński, and Lidia Rutkowska-Sak. Tophi – surgical treatment. Reumatologia., 2016; 54(5): 267–272. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
74.Lee JK, Kim JW, Kim YS, Koo BS. A case of severe gouty tophi-induced carpal tunnel syndrome: Operative finding and its outcome.
Handchir. Mikrochir. Plast. Chir. 2018; 50(1):19-21. (https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428)
75.Khanna D., Khanna P.P., Fitzgerald J.D., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis
Care |
Res. |
(Hoboken). |
2012;64 |
(10):1447–61. |
(https://elibrary.ru/contents.asp?issueid=1838606&selid=29381428) |
||||
76. Abhishek |
A. Managing gout flares |
in the |
elderly: practical |
|
considerations. |
(https://www.ncbi.nlm.nih.gov/pubmed/? |
|||
term=Abhishek%20A%5BAuthor%5D&cauthor=true&cauthor_uid=29214511)Drugs
Aging. |
2017; |
34 |
(12):873-880. |
(https://www.ncbi.nlm.nih.gov/pubmed/29214511) |
|
||
77.Derosa G., Maffioli P., Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol. Res. 2015; (102):63–70. (https://www.ncbi.nlm.nih.gov/pubmed/29214511)
78.Ansquer J.C., Dalton R.N., Caussé E., et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy
people. |
Am. |
J. |
Kidney |
Dis. |
2008; |
(51):904–13. |
(https://www.ncbi.nlm.nih.gov/pubmed/29214511) |
|
|||||
79.Choi H.K., Soriano L.C., Zhang Y., et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012; (344):d8190. (https://www.ncbi.nlm.nih.gov/pubmed/29214511)
80.Ogata N., Fujimori S., Oka Y., et al. Effects of three strong statins
(atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients Nucleosides Nucleotides Nucleic Acids. 2010; (29):321–4. (https://www.ncbi.nlm.nih.gov/pubmed/29214511)
81.Kasper IR, Juriga MD, Giurini JM, et al. Treatment of tophaceous gout: When medication is not enough. Semin Arthritis Rheum. 2016; (45):669-674. (https://www.ncbi.nlm.nih.gov/pubmed/29214511)
82.Dessein P.H., Shipton E.A., Stanwix A.E., Joffe B.I., Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann. Rheum. Dis. 2000; (59):539–43. (https://www.ncbi.nlm.nih.gov/pubmed/29214511)
83.Kullich W., Ulreich A., Klein G. Changes in uric acid and blood lipids in patients with asymptomatic hyperuricemia treated with diet therapy in a rehabilitation procedure [in German]. Rehabilitation. 1989; (28):134–7. (https://www.ncbi.nlm.nih.gov/pubmed/29214511)
84.Choi H.K., Atkinson K., Karlson E.W., Willett W., Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet.